Lexaria Bioscience Corp. (NASDAQ: LEXX) has successfully extended its Material Transfer Agreement with a pharmaceutical partner (PharmaCO) to December 31, 2026, allowing further evaluation of Lexaria’s DehydraTECH™ technology. Over the past year, Lexaria has advanced its GLP-1 development program, currently conducting fully funded studies with results expected in Q3 and Q4 of this year. DehydraTECH™ enhances drug delivery to the bloodstream via oral administration, and Lexaria has a strong intellectual property portfolio with 65 patents. The company warns that forward-looking statements carry risks and uncertainties.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://investingnews.com/material-transfer-agreement-between-pharmaceutical-company-and-lexaria-is-extended-april-2026/
